Sasha Jovanovic
4 min read
Northrop Grumman just posted its Q3 2026 scorecard and the market loved it. The stock jumped about 4.6% today to roughly US$534, a sharp move for a large defense contractor. Traders rushed to price in what looks like one thing above all else: a powerful profitability story.
Q3 segment operating margin landed at 12.1% on US$11.1b of sales, while adjusted free cash flow reached about US$1.8b. That mix of solid defense demand and rich cash generation fed the buying frenzy, leaving a real question for you: Is this a rational repricing or a mood swing around one very strong quarter?
Love Northrop Grumman’s rich margins and hefty free cash flow but want a wider set of stocks with similar financial muscle and balance sheet strength? Move across to our list of solid balance sheet and fundamentals stocks (25 results)
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025): US$11.1b vs. US$10.4b (+6.7%)
-
Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$1,124m vs. US$1,100m (+2.2%)
-
Basic EPS (Q3 2026 vs. Q3 2025): US$7.91 vs. US$7.69 (+2.9%)
-
Segment Operating Margin (Q3 2026 vs. Q3 2025): 12.1% vs. 11.3% (approx., improvement of about 80 bps)
Skip the headline EPS beat. Ask Charlie what Northrop Grumman’s record backlog really signals.
Northrop Grumman: Budget Tailwinds Meeting Execution
The bullish story rests on big programs and capacity buildouts turning into durable earnings power.
“The main requirement for this narrative is continued execution on high visibility programs and capacity buildouts, including B-21, Sentinel, munitions and solid rocket motors, and national security space, while keeping segment margins on track despite pockets of contract pressure and elevated capital expenditure.”
Q3 results lean toward validation. Segment margin reached 12.1% while sales were US$11.1b and backlog climbed to US$110b with a 1.5x book to bill. Aeronautics, Defense Systems and Mission Systems each posted double digit or mid teens profitability. Management still expects higher capex in 2027, yet raised segment operating income and EPS guidance without cutting free cash flow targets.
Northrop Grumman: Testing Execution And Cash Risks
The cautionary view argues that big ticket programs and heavy investment could backfire.
“Execution issues on complex fixed price contracts, as seen in the unfavorable estimate at completion adjustments on the Stand in Attack Weapon program and the GEM 63XL program, show that cost or schedule overruns can quickly compress segment margins and may weigh on company wide net margins and earnings if similar issues occur on other projects.”
